R1 Therapeutics

About R1 Therapeutics

R1 Therapeutics is a biotech company focused on developing innovative first-in-class therapies for patients with kidney disease, aiming to redefine the standard of care in hyperphosphatemia and lead the future of renal care. Their mission is to deliver meaningful change for underserved patients and build a fully integrated, innovation-driven kidney therapeutics company.

Products & Services

AP306:A first-in-class pan phosphate transporter inhibitor for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. It blocks key phosphate active transporters in the gut, offering rapid and effective phosphate lowering with a reduced pill burden.

Specialties

Kidney disease therapeutics Hyperphosphatemia treatment Renal care innovation Phosphate transporter inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 77500000 MR: - FA: $77.5 million FAN: 77500000	D: 2026-03-17 FD: 2026-03-17	6 investors

Series A Latest

2026-03-17

$77.5M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Krishna Polu

Co-Founder, President & CEO

L

L. Mary Smith

Co-Founder & Chief Operating Officer

S

Seema Rogers

VP Clinical Development Operations

L

Lei Lei Sengchanthalangsy

VP Program and Alliance Management

A

Allison Lim

VP Clinical Development

P

Phil Roberts

Head of CMC

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

R1 Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised